Targeted therapies and molecular targets in the therapeutic landscape of advanced urothelial carcinoma: state of the art and future perspectives
Advanced urothelial carcinoma (aUC) has a dismal prognosis, with a 5-year survival rate of approximately 10%. Platinum-based chemotherapy has been the backbone of the first-line treatment of aUC for over 40 years. Only in the last decade, the treatment of aUC has evolved and been enriched with new c...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Open Exploration Publishing Inc.
2024-11-01
|
| Series: | Exploration of Targeted Anti-tumor Therapy |
| Subjects: | |
| Online Access: | https://www.explorationpub.com/Journals/etat/Article/1002279 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846160537711280128 |
|---|---|
| author | Irene Testi Giulia Claire Giudice Giuseppe Salfi Martino Pedrani Sara Merler Fabio Turco Luigi Tortola Ursula Vogl |
| author_facet | Irene Testi Giulia Claire Giudice Giuseppe Salfi Martino Pedrani Sara Merler Fabio Turco Luigi Tortola Ursula Vogl |
| author_sort | Irene Testi |
| collection | DOAJ |
| description | Advanced urothelial carcinoma (aUC) has a dismal prognosis, with a 5-year survival rate of approximately 10%. Platinum-based chemotherapy has been the backbone of the first-line treatment of aUC for over 40 years. Only in the last decade, the treatment of aUC has evolved and been enriched with new classes of drugs that demonstrated pivotal improvements in terms of oncological responses and, ultimately, survival. Thus, the approach to aUC is becoming more and more tailored to the single patient, particularly owing to targeted therapies, such as fibroblast growth factor receptor (FGFR) inhibitors, antibody-drug conjugates (ADCs) targeting TROP2 and Nectin-4, anti-Her-2 therapies and others. However, due to the rapidly evolving scenario, the optimal sequence of systemic treatment is unknown and several important research questions remain unanswered, including the identification of reliable biomarkers to guide treatment decisions. Through ongoing research and clinical trials, we can continue to refine personalized treatment strategies and ultimately enhance patient care in this challenging disease setting. In this review, we provide a comprehensive overview of the current and emerging landscape of targeted therapies for aUC. We delved into the opportunities and challenges presented by personalized treatment approaches and explored potential future directions in this rapidly evolving field. |
| format | Article |
| id | doaj-art-50345d19217b432891d671f63e69aa3f |
| institution | Kabale University |
| issn | 2692-3114 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | Open Exploration Publishing Inc. |
| record_format | Article |
| series | Exploration of Targeted Anti-tumor Therapy |
| spelling | doaj-art-50345d19217b432891d671f63e69aa3f2024-11-22T06:05:51ZengOpen Exploration Publishing Inc.Exploration of Targeted Anti-tumor Therapy2692-31142024-11-01561326136410.37349/etat.2024.00279Targeted therapies and molecular targets in the therapeutic landscape of advanced urothelial carcinoma: state of the art and future perspectivesIrene Testi0Giulia Claire Giudice1Giuseppe Salfi2Martino Pedrani3Sara Merler4Fabio Turco5Luigi Tortola6Ursula Vogl7Oncology Institute of Southern Switzerland (IOSI), Ente Ospedaliero Cantonale (EOC), 6500 Bellinzona, Switzerland; Medical Oncology Unit, University Hospital of Parma, 43123 Parma, ItalyMedical Oncology Unit, University Hospital of Parma, 43123 Parma, ItalyOncology Institute of Southern Switzerland (IOSI), Ente Ospedaliero Cantonale (EOC), 6500 Bellinzona, Switzerland; Institute of Oncology Research (IOR), 6500 Bellinzona, SwitzerlandOncology Institute of Southern Switzerland (IOSI), Ente Ospedaliero Cantonale (EOC), 6500 Bellinzona, Switzerland; Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, 20162 Milan, ItalyOncology Institute of Southern Switzerland (IOSI), Ente Ospedaliero Cantonale (EOC), 6500 Bellinzona, Switzerland; Institute of Oncology Research (IOR), 6500 Bellinzona, Switzerland; Section of Innovation Biomedicine-Oncology Area, Department of Engineering for Innovation Medicine, University of Verona and Verona University Hospital Trust, 37129 Verona, Italy; Faculty of Biomedical Sciences, Università della Svizzera Italiana, 6900 Lugano, SwitzerlandOncology Institute of Southern Switzerland (IOSI), Ente Ospedaliero Cantonale (EOC), 6500 Bellinzona, SwitzerlandOncology Institute of Southern Switzerland (IOSI), Ente Ospedaliero Cantonale (EOC), 6500 Bellinzona, SwitzerlandOncology Institute of Southern Switzerland (IOSI), Ente Ospedaliero Cantonale (EOC), 6500 Bellinzona, SwitzerlandAdvanced urothelial carcinoma (aUC) has a dismal prognosis, with a 5-year survival rate of approximately 10%. Platinum-based chemotherapy has been the backbone of the first-line treatment of aUC for over 40 years. Only in the last decade, the treatment of aUC has evolved and been enriched with new classes of drugs that demonstrated pivotal improvements in terms of oncological responses and, ultimately, survival. Thus, the approach to aUC is becoming more and more tailored to the single patient, particularly owing to targeted therapies, such as fibroblast growth factor receptor (FGFR) inhibitors, antibody-drug conjugates (ADCs) targeting TROP2 and Nectin-4, anti-Her-2 therapies and others. However, due to the rapidly evolving scenario, the optimal sequence of systemic treatment is unknown and several important research questions remain unanswered, including the identification of reliable biomarkers to guide treatment decisions. Through ongoing research and clinical trials, we can continue to refine personalized treatment strategies and ultimately enhance patient care in this challenging disease setting. In this review, we provide a comprehensive overview of the current and emerging landscape of targeted therapies for aUC. We delved into the opportunities and challenges presented by personalized treatment approaches and explored potential future directions in this rapidly evolving field.https://www.explorationpub.com/Journals/etat/Article/1002279advanced urothelial carcinomatargeted therapybladder cancerfibroblast growth factor receptortrop2nectin-4tkisher-2 |
| spellingShingle | Irene Testi Giulia Claire Giudice Giuseppe Salfi Martino Pedrani Sara Merler Fabio Turco Luigi Tortola Ursula Vogl Targeted therapies and molecular targets in the therapeutic landscape of advanced urothelial carcinoma: state of the art and future perspectives Exploration of Targeted Anti-tumor Therapy advanced urothelial carcinoma targeted therapy bladder cancer fibroblast growth factor receptor trop2 nectin-4 tkis her-2 |
| title | Targeted therapies and molecular targets in the therapeutic landscape of advanced urothelial carcinoma: state of the art and future perspectives |
| title_full | Targeted therapies and molecular targets in the therapeutic landscape of advanced urothelial carcinoma: state of the art and future perspectives |
| title_fullStr | Targeted therapies and molecular targets in the therapeutic landscape of advanced urothelial carcinoma: state of the art and future perspectives |
| title_full_unstemmed | Targeted therapies and molecular targets in the therapeutic landscape of advanced urothelial carcinoma: state of the art and future perspectives |
| title_short | Targeted therapies and molecular targets in the therapeutic landscape of advanced urothelial carcinoma: state of the art and future perspectives |
| title_sort | targeted therapies and molecular targets in the therapeutic landscape of advanced urothelial carcinoma state of the art and future perspectives |
| topic | advanced urothelial carcinoma targeted therapy bladder cancer fibroblast growth factor receptor trop2 nectin-4 tkis her-2 |
| url | https://www.explorationpub.com/Journals/etat/Article/1002279 |
| work_keys_str_mv | AT irenetesti targetedtherapiesandmoleculartargetsinthetherapeuticlandscapeofadvancedurothelialcarcinomastateoftheartandfutureperspectives AT giuliaclairegiudice targetedtherapiesandmoleculartargetsinthetherapeuticlandscapeofadvancedurothelialcarcinomastateoftheartandfutureperspectives AT giuseppesalfi targetedtherapiesandmoleculartargetsinthetherapeuticlandscapeofadvancedurothelialcarcinomastateoftheartandfutureperspectives AT martinopedrani targetedtherapiesandmoleculartargetsinthetherapeuticlandscapeofadvancedurothelialcarcinomastateoftheartandfutureperspectives AT saramerler targetedtherapiesandmoleculartargetsinthetherapeuticlandscapeofadvancedurothelialcarcinomastateoftheartandfutureperspectives AT fabioturco targetedtherapiesandmoleculartargetsinthetherapeuticlandscapeofadvancedurothelialcarcinomastateoftheartandfutureperspectives AT luigitortola targetedtherapiesandmoleculartargetsinthetherapeuticlandscapeofadvancedurothelialcarcinomastateoftheartandfutureperspectives AT ursulavogl targetedtherapiesandmoleculartargetsinthetherapeuticlandscapeofadvancedurothelialcarcinomastateoftheartandfutureperspectives |